ARKAY Therapeutics, LogoFollow Us:LinkedIn
Phone Icon (609) 362-6818

Dr. Ravi Kumar

Ravi Kumar, Ph.D.
President and CEO, Board Member

Dr. Ravi Kumar has served as the CEO and Scientific Director since 2014. He founded ARKAY with a mission to provide long-term glycemic control to Type 2 diabetes patients. Dr. Kumar has a unique combination of drug discovery and development expertise in metabolic, cardiovascular, CNS and chronic inflammatory diseases.

Read More


Dr. Alan Lewis

Alan J. Lewis, Ph.D. Board Member
President and CEO, Diavacs 

Dr. Alan J. Lewis is the President, CEO and board member of DiaVacs, a Type 1 diabetes company. DiaVacs is developing products to reverse the onset of autoimmune diseases by reinducing tolerance into the patient's immune system.

Read More 


Stanley Schwartz, M.D., FACP, FACE, Advisor

Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, PA. 

Dr. Stanley Schwartz is a renowned endocrinologist, an expert and a key opinion leader in diabetes and cardiometabolic syndrome. Dr. Schwartz actively lectures nationally, as well as internationally, about diabetes and its treatment. In the past 4 years he has been a speaker in Turks/Caicos, Istanbul, Switzerland , Belgium, Tunisia, Spain, 11 cities in China, Phillipines (AACE), Israel, Singapore and AACE 2011/2014, ADA 2014-(2015) and in October 2016 at Korean Diabetes Assoc.

Read More

Stanley Schwartz

Dr. Jialal

Ishwarlal Jialal, M.D., Ph.D. Advisor

Distinguished Professor of Pathology and Laboratory Medicine
Endocrinology, Diabetes and Metabolism (Retired)
Director of Laboratory for Atherosclerosis and Metabolic Research
Director, Special Chemistry and Toxicology
University of California Davis Medical. Currently in private practice.

Editor-in-chief of Metabolic Syndrome and Related Disorders (2007-17)

Dr. Jialal has published over 380 original papers and invited reviews in the areas of diabetes, atherosclerosis, lipid metabolism, nutrition and vascular biology. He has received numerous awards for his research, and has served on the editorial boards of numerous journals, including: American Journal of Clinical Nutrition, Journal of Molecular and Cellular Cardiology and Atherosclerosis. Currently, Dr. Jialal serves as section editor of the American Journal of Clinical Pathology for Clinical Chemistry and editor-in-chief of Metabolic Syndrome and Related Disorders.

Read More


Dr. Nancy Motola

Nancy C. Motola, PhD, RAC, Advisor

Former Senior Vice President of
Regulatory & Quality,
Alexion Pharmaceuticals Inc.

Nancy C. Motola, PhD, RAC, has over 30 years' experience in the Pharmaceutical Industry, encompassing both small molecules, biologics, and many therapeutic areas, in regulatory affairs and quality assurance, as well as chemical development/manufacturing.  Through her consulting company, Pharma Regulatory Connection, she provides strategic Regulatory expertise for small/start-up, as well as large pharma companies.

Read More


Casey Case, Ph.D. Board member

Senior Vice President, Research & Nonclinical Development, Asterias Biotherapeutics

CASEY CASE, Ph.D. is senior vice president of research and nonclinical development at Asterias Biotherapeutics. Asterias is developing embryonic cell-based therapies for spinal cord injury and cancer.

Read More

Casey Case

Milton H. Grannatt, Ph.D. Board member

Retired Vice President, Global Business Development & Licensing
Novartis Pharmaceuticals Corporation 

Dr. Grannatt retired September 2012 after 25 years in the global pharmaceuticals industry.  He was Vice President of Global Business Development and Licensing at Novartis.  Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive, diversified UK-based company. Dr. Grannatt has an extensive deal sheet.

Read More

Dr. Milton Grannatt

Dr. Ravi Kumar

Paul Jeffrey, M.B.A. Board member

Former Vice President, New Product Development & Commercialization, Pfizer

Mr. Paul Jeffrey is an experienced business executive and advisor with over 35 years of pharmaceutical research, product development, marketing and business development experience. As vice president of early commercial development at Pfizer, he was responsible for commercial development of the entire portfolio of Rx pipeline products in Primary Care.

Read More


Martin Ogletree, Ph.D. Advisor

Former Distinguished Research Fellow and Director of Thrombosis
Research, Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb

Dr. Ogletree led thrombosis research in Cardiovascular Drug Discovery at Merck Research Labs and at Bristol-Myers Squibb. At Merck he also led target identification and validation for the cardiovascular franchise.

Read More

Dr. Martin Ogletree

Clifford M. Davidson, Advisor

Intellectual Property Attorney, Founding Partner, Davidson, Davidson &
Kappel, LLC

Clifford is a founding partner at Davidson, Davidson & Kappel, LLC, an Intellectual Property law firm with offices in New York. He counsels pharmaceutical clients in pharmaceutical patent-related matters, including patent prosecution, freedom to operate and infringement opinions, due diligence and techtransfer, and litigation. He has assisted pharmaceutical and biotech companies in creating significant and valuable patent portfolios covering their proprietary technologies.

Read More 

CLIFFORD M. DAVIDSON


Hemant N. Joshi, Ph.D. MBA, Advisor

Founder, TARA Innovations, LLC.

Dr. Hemant Joshi is the founder of Tara Innovations LLC, a Pharmaceutical product development Contract Research Organization (CRO). He has over 27 years' experience as a Pharmaceutical Scientist. Tara is involved in product development, analysis and technology management.

Read More 

Hemant N. Joshi